Differentiating agents in pediatric malignancies: All-trans-retinoic acid and arsenic in acute promyelocytic leukemia

被引：20

作者：

Calleja E.M. ^{[1
]}

Warrell R.P. ^{[2
]}

Jr ^{[2
]}

机构：

[1] Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021

[2] Genta Incorporated, Berkeley Heights, NJ, 07922

来源：

Current Oncology Reports | 2000年 / 2卷 / 6期

关键词：

Arsenic; Acute Myeloid Leukemia; Retinoic Acid; Acute Promyelocytic Leukemia; Arsenic Trioxide;

D O I：

10.1007/s11912-000-0105-x

中图分类号：

学科分类号：

摘要：

Acute promyelocytic leukemia (APL) is the most potentially curable type of acute myeloid leukemia. It is characterized by the chromosomal translocation t(15;17), which results in the fusion gene PML-RAR-alpha. The introduction of all-trans- retinoic acid (ATRA) was a major advance in treatment of this disease. This agent induces terminal differentiation of malignant myeloid cells to mature neutrophils, and its side effects are usually well tolerated in children. ATRA does not eradicate the malignant myeloid clone in APL and, eventually, resistance develops. Arsenic trioxide induces nonterminal differentiation of malignant promyelocytes and promotes apoptosis. APL patients treated with ATRA or arsenic trioxide have rapid resolution of their coagulopathy. Because both of these drugs are well tolerated in children and their synergy has been shown in animal models, the possibility of combining ATRA and arsenic trioxide in front-line therapy for children with APL is being considered.

引用

页码：519 / 523

页数：4

共 42 条

[31]

Jackson R, Grainge JW, Arsenic and cancer, Can Med Assoc J, 113, pp. 396-401, (1975)

[32]

Forkner C, McNair-Scott TF, Arsenic as a therapeutic agent in chronic myeloid leukemia, JAMA, 97, pp. 305-305, (1931)

[33]

Kandel EV, LeRoy GV, Chronic arsenical poisoning during the treatment of chronic myeloid leukaemia, Arch Intern Med, 60, pp. 846-866, (1937)

[34]

Zhang P, Wang SY, Hu XH, Arsenic trioxide treated 72 cases of acute promyelocytic leukemia, Chin J Hematol, 17, pp. 58-62, (1996)

[35]

Shen ZX, Chen GQ, Ni JH, Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients, Blood, 89, pp. 3354-3360, (1997)

[36]

Soignet S, Maslak P, Wang ZG, Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide, N Engl J Med, 339, pp. 1341-1348, (1998)

[37]

Zhu J, Guo W, Yao Y, Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents, Leukemia, 13, pp. 1062-1070, (1999)

[38]

Chen GQ, Zhu J, Shi XG, In vitro studies on cellular and molecular mechanisms of arsenic trioxide(As2O3) in the treatment of acute promyeloctyic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins, Blood, 88, pp. 1052-1061, (1996)

[39]

Dai J, Weinberg RS, Waxman S, Jing Y, Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the gluthathione redox system, Blood, 93, pp. 268-277, (1999)

[40]

Jing Y, Dai J, Chalmers-Redman RM, Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway, Blood, 94, pp. 2102-2111, (1999)

← 1 2 3 4 5 →